GSK files regulatory submission with US FDA for FF / UMEC / VI therapy

GlaxoSmithKline (GSK) and Innoviva have filed a regulatory submission with the US Food and Drug Administration (FDA) for fluticasone furoate / umeclidinium / vilanterol (FF / UMEC / VI 100mcg / 62.5mcg / 25mcg) therapy for patients with chronic obstr …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news